Cynata Therapeutics Limited (ASX:CYP)
0.3750
+0.0150 (4.17%)
Apr 20, 2026, 3:58 PM AEST
Cynata Therapeutics Revenue
Cynata Therapeutics had revenue of 1.77M AUD in the half year ending December 31, 2025, a decrease of -30.38%. This brings the company's revenue in the last twelve months to 1.69M, down -3.03% year-over-year. In the fiscal year ending June 30, 2025, Cynata Therapeutics had annual revenue of 1.89M, down -18.59%.
Revenue (ttm)
1.69M
Revenue Growth
-3.03%
P/S Ratio
51.37
Revenue / Employee
843.64K
Employees
2
Market Cap
86.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.89M | -430.50K | -18.59% |
| Jun 30, 2024 | 2.32M | 661.33K | 39.98% |
| Jun 30, 2023 | 1.65M | -6.12M | -78.71% |
| Jun 30, 2022 | 7.77M | 6.22M | 402.60% |
| Jun 30, 2021 | 1.55M | -5.47M | -77.95% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Botanix Pharmaceuticals | 21.92M |
| Radiopharm Theranostics | 16.28M |
| Immutep | 7.92M |
| Alterity Therapeutics | 6.64M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
| Prescient Therapeutics | 4.27M |
| Arovella Therapeutics | 3.21M |